This filing is a routine promotional 425 with no material new information. Traders should monitor for the filing of the S-4 registration statement and the proxy statement, which will contain the key financial details and voting timeline. The webinar may generate short-term retail interest, but the deal's completion risk remains high given the small NDRA ownership stake and regulatory hurdles.
Price Chart
Executive Summary
ENDRA Life Sciences (NDRA) filed a 425 communication announcing a RedChip investor webinar for July 21, 2026, featuring Paul Mann (CEO of ASP Isotopes and Renergen) to discuss the proposed merger with Noble Africa and the Virginia Gas Project. The webinar is a promotional event for the already-announced reverse merger where NDRA shareholders will receive ~3% of the combined company (Noble Africa Inc.), with the deal expected to close in Q3 or Q4 2026. No changes to deal terms or new financial information were disclosed.
Key Financial Metrics
Key Facts
- RedChip investor webinar scheduled for July 21, 2026 at 4:15 PM ET to promote the proposed merger of Noble Africa with ENDRA.
- Deal terms unchanged: ENDRA shareholders to own ~3% of combined company, ASPI ~89%, private placement investors ~7%.
- Concurrent private placement of ~$50 million (including ~$20M from ASPI) expected to close before the merger.
- Combined company to be named Noble Africa Inc., trading under ticker 'NOBA' on Nasdaq upon closing.
- Merger expected to close in Q3 or Q4 2026, subject to SEC registration, ENDRA stockholder approval, and other customary conditions.
Financial Impact
No financial figures reported in this filing. Prior filings indicate a ~$50M private placement and ownership split of ~89% ASPI, ~3% NDRA, ~7% placement investors.
Risk Factors
- ENDRA stockholders face massive dilution, owning only ~3% of the combined company.
- Deal may fail to close due to stockholder disapproval, SEC delays, or failure to secure the private placement.
- The combined company's future depends on Renergen's Virginia Gas Project reaching Phase 1/2 production, which carries operational and funding risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-078913 |
| Document: 0001213900-26-078913-index-headers.html | 0001213900-26-078913 |
| Document: 0001213900-26-078913-index.html | 0001213900-26-078913 |
| Document: 0001213900-26-078913.txt | 0001213900-26-078913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $4.82 | awaiting T+5 | — | $4.96 (+2.93%) |
Oct 8, 2026 19d ago | 3 | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 8, 2026 19d ago | SC 13D | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 1, 2026 26d ago | 425 | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Oct 1, 2026 26d ago | 8-K | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Sep 25, 2026 4w ago | 425 | $5.80 $6.31 | ▲ +8.79% | ▲ +7.59% | $4.96 (−14.47%) |
Sep 9, 2026 6w ago | 425 | $5.83 $5.13 | ▼ −12.01% | ▼ −11.67% | $4.96 (−14.91%) |
Aug 17, 2026 10w ago | 8-K | $4.51 $4.75 | ▲ +5.32% | ▲ +5.52% | $4.96 (+10.00%) |
Jul 17, 2026 14w ago | 425 | $4.99 $5.23 | ▲ +4.81% | ▲ +5.50% | $4.96 (−0.58%) |
Jul 9, 2026 15w ago | 8-K | $5.49 $5.27 | ▼ −4.01% | ▼ −3.88% | $4.96 (−9.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers